Zynerba Pharmaceuticals (NASDAQ: ZYNE) recently received a number of ratings updates from brokerages and research firms:

  • 12/4/2017 – Zynerba Pharmaceuticals was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 12/4/2017 – Zynerba Pharmaceuticals was given a new $18.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 11/20/2017 – Zynerba Pharmaceuticals was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 11/18/2017 – Zynerba Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. “
  • 11/14/2017 – Zynerba Pharmaceuticals had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings Inc..
  • 11/14/2017 – Zynerba Pharmaceuticals had its price target raised by analysts at Piper Jaffray Companies from $16.00 to $20.00.
  • 10/18/2017 – Zynerba Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. “
  • 10/12/2017 – Zynerba Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $11.00 price target on the stock. According to Zacks, “Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. “

Shares of Zynerba Pharmaceuticals, Inc. (NASDAQ ZYNE) traded down $0.36 during mid-day trading on Wednesday, reaching $13.01. The company’s stock had a trading volume of 381,700 shares, compared to its average volume of 641,867. Zynerba Pharmaceuticals, Inc. has a 52-week low of $5.42 and a 52-week high of $25.95.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.05). During the same period in the previous year, the company earned ($0.67) earnings per share. sell-side analysts forecast that Zynerba Pharmaceuticals, Inc. will post -2.49 EPS for the current year.

In other news, major shareholder Michael Rapp purchased 25,745 shares of the company’s stock in a transaction on Monday, October 23rd. The stock was purchased at an average price of $9.94 per share, with a total value of $255,905.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 9.91% of the company’s stock.

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Receive News & Ratings for Zynerba Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.